GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
 & Lead Plaintiff Deadline: March 27, 2017 - EconoTimes)
NEW YORK, Feb. 09, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (NASDAQ:RWLK) and certain of its officers, on behalf of a class who purchased ReWalk securities pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014. Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rwlk.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
ReWalk is a medical commercial bionic walking assistance system. The company designs, develops, and commercializes exoskeletons for wheelchair-bound individuals.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements in its Registration Statement and Prospectus issued in regards with the Initial Public Offering did not disclose material information, including that ReWalk could not comply with “special controls” requirements or to offer the U.S. Food and Drug Administration with a post market surveillance study. Once this information was made public, ReWalk stock price dropped, causing investors harm.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/rwlk or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
